NCT03752398 - A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) | Biotech Hunter

Enrollment

198

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

February 15, 2024

Study Completion Date

February 15, 2024

Conditions

Melanoma (Excluding Uveal Melanoma)Cervical CarcinomaPancreatic CarcinomaBreast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 NegativeHepatocellular CarcinomaUrothelial CarcinomaSquamous Cell Carcinoma of the Head and NeckNasopharyngeal CarcinomaRenal Cell CarcinomaColorectal CarcinomaEndometrial CarcinomaNon-small Cell Lung CarcinomaSmall Cell Lung CancerGastric or Gastroesophageal Junction AdenocarcinomaAdvanced Solid TumorsUndifferentiated Pleomorphic Sarcoma

Interventions

BIOLOGICAL

XmAb®23104

Monoclonal bispecific antibody

BIOLOGICAL

Yervoy® (ipilimumab)

Monoclonal antibody

Trial Locations (18)

10032

Columbia University Medical Center, New York

15232

UPMC Hillman Cancer Center, Pittsburgh

19104

University of Pennsylvania Abramson Cancer Center, Philadelphia

22903

Emily Couric Clinical Cancer Center, Charlottesville

27710

Duke Cancer Institute, Durham

30322

Emory University, Atlanta

34232

Florida Cancer Specialists, Sarasota

48109

University of Michigan, Ann Arbor

52242

University of Iowa Hospitals and Clinics, Iowa City

63110

Washington University School of Medicine Siteman Cancer Center, St Louis

75230

Mary Crowley Cancer Research - Medical City, Dallas

77030

The University of Texas MD Anderson Cancer Center, Houston

80045

University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora

80218

Sarah Cannon Research Institute at HealthONE, Denver

84112

University of Utah, Huntsman Cancer Institute, Salt Lake City

92093

UC San Diego Moores Cancer Center, San Diego

97213

Providence Portland Medical Center, Portland

98109

Seattle Cancer Care Alliance, Seattle